Archives
All the articles I've archived.
-
Ch. II — Chemistry and pharmacology
Structural scaffolds, synthesis, stability, and pharmacokinetics for psilocybin/psilocin, DMT, LSD, 5-MeO-DMT, and the fluoroethyl lysergamides.
-
Ch. VI — Clinical evidence: addiction, PTSD, anorexia, OCD
Psilocybin in AUD and tobacco cessation; the MAPP1/MAPP2 MDMA-AT case study; small-sample signals; ibogaine sidebar.
-
Ch. VIII — Fluoroethyl lysergamides
Structural pharmacology and harm-reduction epistemology of FLUORETH-LAD, FP-LAD, and the 1Fe-LSD ferrocenyl naming collision.
-
Ch. VII — Mebufotenin (5-MeO-DMT) clinical program
Two competing Phase 2b programmes — Beckley/atai BPL-003 and GH Research GH001 — and the implausibly-large GH001 effect-size decomposition.
-
Ch. I — Historical arc and sociocultural reframing
Traces the field from Hofmann's 1943 LSD synthesis through Schedule I, the 1990s–2000s renaissance triggers, 2010s mainstreaming, and the 2024 Lykos correction.
-
Ch. XII — Methodology, adverse events, and ethics
Cochrane RoB 2.0 applied to flagship trials with worked Muthukumaraswamy 2021 expectancy correction; functional unblinding; suicidality and HPPD; the Lykos MP-4 misconduct forensics.
-
Ch. IX — Cognitive enhancement and microdosing
The placebo-controlled microdosing literature; the expectancy-dominated honest verdict; real neurophysiology without behavioural translation; chronic 5-HT2B safety.
-
Ch. IV — Systems neuroscience and mechanism
DMN disintegration, entropy, REBUS; the dendritic-spine plasticity literature; the intracellular 5-HT2A thesis; durable connectivity changes.
-
Ch. V — Clinical evidence: depression and anxiety
Psilocybin TRD and MDD; LSD anxiety; MM120 GAD; meta-analytic comparison; Cochrane RoB 2.0 critique; ketamine as comparator.
-
Post-2010 Psychedelics: An Expert-Panel Review
A ~65,000-word, thirteen-chapter interdisciplinary review of post-2010 psychedelic developments — clinical evidence, receptor biology and neuroplasticity, regulatory landscape, methodology critique, and sociocultural context including Indigenous reciprocity. Verified-citation, placebo-honest, post-Lykos.
-
Ch. III — Receptor biology and signaling bias
Why 5-HT2A is necessary but not sufficient; Gq vs β-arrestin; the 2022–2025 cryo-EM atlas; the non-hallucinogenic 5-HT2A agonist frontier.
-
Ch. XI — Regulatory and legal landscape
US federal status; FDA BTD timeline; the Lykos regulatory episode; Oregon Measure 109; Colorado Prop 122; Australia, EU/UK, Canada; pharma economics; REMS architecture and DEA scheduling.
-
Ch. XIII — Synthesis & outlook
Convergent findings, open questions, five-to-ten year research agenda, and reflexive acknowledgment of Western-academic sourcing.
-
Ch. X — Therapy model, set and setting, Indigenous reciprocity
Hartogsohn framework; music; credentialing patchwork; differentiated Indigenous traditions; the structural reciprocity gap with named source communities and pharma beneficiaries.
-
Notes on cheetahs
The calmest cat, the dogs that calm them, and the visitor's responsibility.